Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups

Journal of Korean Medical Science

Volumn 28, Issue 8, 2013, Pages 1129-1133

  Shin, Joong Gon ^a   Cheong, Hyun Sub ^b   Kim, Jason Yongha ^a   Kim, Lyoung Hyo ^b   Han, Chang Soo ^b   Kim, Ji On ^b   Kim, Hae Deun ^c   Kim, Young Hoon ^c   Chung, Myeon Woo ^c   Han, Soon Young ^c   Shin, Hyoung Doo ^a,b  

^a Sogang University   (South Korea)

^b SNP Genetics Inc   (South Korea)

^c National Institute of Food and Drug Safety Evaluation   (South Korea)

Author keywords

Dihydropyrimidine dehydrogenase; Ethnic gropus; Fluorouracil; Pharmacogenetics

Indexed keywords

AMINO ACID; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL;

AFRICAN AMERICAN; ALLELE; ARTICLE; ASIAN; CAUCASIAN; DNA SEQUENCE; ETHNIC GROPUS; ETHNIC GROUP; GENE FREQUENCY; GENETICS; GENOTYPE; HUMAN; METABOLISM; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

DIHYDROPYRIMIDINE DEHYDROGENASE; ETHNIC GROPUS; FLUOROURACIL; PHARMACOGENETICS;

AFRICAN AMERICANS; ALLELES; AMINO ACIDS; ASIAN CONTINENTAL ANCESTRY GROUP; DIHYDROURACIL DEHYDROGENASE (NADP); ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FLUOROURACIL; GENE FREQUENCY; GENOTYPE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA;

EID: 84884402563     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.8.1129     Document Type: Article

References (36)

1. Savonarola A, Palmirotta R, Guadagni F, Silvestris F. Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. Pharmacogenomics J 2012; 12: 277-86.
2. Kristyanto H, Utomo AR. Pharmacogenetic application in personalized cancer treatment. Acta Med Indones 2010; 42: 109-15.
3. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37.
4. Milano G, McLeod HL. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment? Eur J Cancer 2000; 36: 37-42.
5. Amstutz U, Froehlich TK, Largiadèr CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics 2011; 12: 1321-36.
6. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.
7. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 2002; 3: 485-92.
8. Cerić T, Obralić N, Kapur-Pojskić L, Macić D, Beslija S, Pasić A, Cerić S. Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine. Bosn J Basic Med Sci 2010; 10: 133-9.
9. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 2005; 11: 8699-705.
10. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin Cancer Res 2002; 8: 768-74.
11. Van Kuilenburg AB, Dobritzsch D, Meinsma R, Haasjes J, Waterham HR, Nowaczyk MJ, Maropoulos GD, Hein G, Kalhoff H, Kirk JM, et al. Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure. Biochem J 2002; 364: 157-63.
12. Van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, van Gennip AH. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 1997; 33: 2258-64.
13. Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clin Cancer Res 2003; 9: 3021-8.
14. Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer 2004; 4: 181-9.
15. Thompson D, Stram D, Goldgar D, Witte JS. Haplotype tagging single nucleotide polymorphisms and association studies. Hum Hered 2003; 56: 48-55.
16. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21: 237-42.
17. McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, et al. Nomenclature for human DPYD alleles. Pharmacogenetics 1998; 8: 455-9.
18. Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYDz.ast;2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemother Pharmacol 2007; 60: 503-7.
19. Van Kuilenburg AB, Vreken P, Abeling NG, Bakker HD, Meinsma R, Van Lenthe H, De Abreu RA, Smeitink JA, Kayserili H, Apak MY, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet 1999; 104: 1-9.
20. Vreken P, Van Kuilenburg AB, Meinsma R, van Gennip AH. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet 1997; 101: 333-8.
21. Kelemen LE, Goodman MT, McGuire V, Rossing MA, Webb PM, Köbel M, Anton-Culver H, Beesley J, Berchuck A, Brar S, et al. Genetic variation in TYMS in the one-carbon transfer pathway is associated with ovarian carcinoma types in the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev 2010; 19: 1822-30.
22. Maekawa K, Saeki M, Saito Y, Ozawa S, Kurose K, Kaniwa N, Kawamoto M, Kamatani N, Kato K, Hamaguchi T, et al. Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences. J Hum Genet 2007; 52: 804-19.
23. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics 2000; 10: 217-23.
24. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit 2007; 29: 190-6.
25. Zhang H, Li YM, Zhang H, Jin X. DPYDz.ast;5 gene mutation contributes to the reduced DPYD enzyme activity and chemotherapeutic toxicity of 5-FU: results from genotyping study on 75 gastric carcinoma and colon carcinoma patients. Med Oncol 2007; 24: 251-8.
26. Yamaguchi K, Arai Y, Kanda Y, Akagi K. Germline mutation of dihydropyrimidine dehydrogenese gene among a Japanese population in relation to toxicity to 5-Fluorouracil. Jpn J Cancer Res 2001; 92: 337-42.
27. Amstutz U, Farese S, Aebi S, Largiadèr CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics 2009; 10: 931-44.
28. Savva-Bordalo J, Ramalho-Carvalho J, Pinheiro M, Costa VL, Rodrigues A, Dias PC, Veiga I, Machado M, Teixeira MR, Henrique R, et al. Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. BMC Cancer 2010; 10: 470.
29. Yaman I, Fernandez J, Liu H, Caprara M, Komar AA, Koromilas AE, Zhou L, Snider MD, Scheuner D, Kaufman RJ, et al. The zipper model of translational control: a small upstream ORF is the switch that controls structural remodeling of an mRNA leader. Cell 2003; 113: 519-31.
30. Hellen CU, Sarnow P. Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 2001; 15: 1593-612.
31. Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene 2004; 23: 3200-7.
32. Chatterjee S, Pal JK. Role of 5'- and 3'-untranslated regions of mRNAs in human diseases. Biol Cell 2009; 101: 251-62.
33. Conklin D, Jonassen I, Aasland R, Taylor WR. Association of nucleotide patterns with gene function classes: application to human 3' untranslated sequences. Bioinformatics 2002; 18: 182-9.
34. Hirota T, Date Y, Nishibatake Y, Takane H, Fukuoka Y, Taniguchi Y, Burioka N, Shimizu E, Nakamura H, Otsubo K, et al. Dihydropyrimidine dehydrogenase (DPD) expression is negatively regulated by certain microRNAs in human lung tissues. Lung Cancer 2012; 77: 16-23.
35. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350-5.
36. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 2004; 3: 739-48.